Compare LKFN & CGEM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LKFN | CGEM |
|---|---|---|
| Founded | 1872 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.4B |
| IPO Year | 2009 | 2020 |
| Metric | LKFN | CGEM |
|---|---|---|
| Price | $60.58 | $20.59 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 8 |
| Target Price | ★ $67.00 | $30.13 |
| AVG Volume (30 Days) | 124.1K | ★ 722.5K |
| Earning Date | 04-27-2026 | 05-11-2026 |
| Dividend Yield | ★ 3.49% | N/A |
| EPS Growth | ★ 10.47 | N/A |
| EPS | ★ 2.17 | N/A |
| Revenue | ★ $985,000.00 | N/A |
| Revenue This Year | $15.50 | N/A |
| Revenue Next Year | $5.51 | $5.20 |
| P/E Ratio | $27.75 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $54.36 | $5.68 |
| 52 Week High | $66.82 | $23.19 |
| Indicator | LKFN | CGEM |
|---|---|---|
| Relative Strength Index (RSI) | 47.44 | 52.22 |
| Support Level | $60.19 | $11.87 |
| Resistance Level | $61.17 | $23.19 |
| Average True Range (ATR) | 1.00 | 0.87 |
| MACD | 0.09 | -0.25 |
| Stochastic Oscillator | 62.11 | 21.52 |
Lakeland Financial Corp is a bank holding company. It provides commercial, retail, wealth advisory, and investment management services. It offers a broad line of products and services throughout its Northern and Central Indiana markets. The company provides commercial and consumer banking services, as well as trust and wealth management, brokerage, and treasury management commercial services. It serves a wide variety of industries including, among others, commercial real estate, manufacturing, agriculture, construction, retail, wholesale, finance and insurance, accommodation and food services, and healthcare. The company's revenue is derived from the business of banking.
Cullinan Therapeutics Inc is a clinical-stage biopharmaceutical company developing therapies for autoimmune diseases and cancer. Its development pipeline comprises the following drug candidates: CLN-978, a CD19xCD3 bispecific T cell engager that is being developed for autoimmune diseases; CLN-049, a FLT3xCD3 bispecific T cell engager being evaluated in an ongoing clinical trial in patients with relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS); Velinotamig, a BCMAxCD3 bispecific T cell engager being developed to counter autoimmune diseases; and Zipalertinib, being developed as a treatment for non-small cell lung cancer. Additionally, the company is developing several preclinical programs in autoimmune diseases and oncology.